Global Patent Index - EP 0851757 A2

EP 0851757 A2 19980708 - A METHOD OF REDUCING THE AMOUNT OF EXOGENOUS INSULIN ADMINISTERED TO A PATIENT HAVING NONINSULIN-DEPENDENT DIABETES MELLITUS

Title (en)

A METHOD OF REDUCING THE AMOUNT OF EXOGENOUS INSULIN ADMINISTERED TO A PATIENT HAVING NONINSULIN-DEPENDENT DIABETES MELLITUS

Title (de)

METHODE ZUR VERRINGERUNG DER EXOGENEN INSULINZUFUHR BEI PATIENTEN MIT NICHT-INSULIN-ABHÄNGIGEN DIABETES MELLITUS

Title (fr)

PROCEDE PERMETTANT DE REDUIRE LA QUANTITE D'INSULINE EXOGENE ADMINISTREE A UN PATIENT SOUFFRANT DE DIABETE SUCRE NON-INSULINODEPENDANT

Publication

EP 0851757 A2 19980708 (EN)

Application

EP 96926171 A 19960729

Priority

  • US 9612430 W 19960729
  • US 209895 P 19950810

Abstract (en)

[origin: WO9705875A2] This invention provides a method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus by administering to a patient a therapeutically effective amount of a thiazolidione derivative and/or a related compound.

IPC 1-7

A61K 31/425

IPC 8 full level

A61K 31/00 (2006.01); C07D 417/12 (2006.01); A61K 31/41 (2006.01); A61K 31/425 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 38/28 (2006.01); A61P 5/50 (2006.01)

CPC (source: EP KR)

A61K 31/41 (2013.01 - EP); A61K 31/425 (2013.01 - KR); A61K 31/426 (2013.01 - EP); A61K 31/427 (2013.01 - EP); A61K 31/4439 (2013.01 - EP); A61K 38/28 (2013.01 - EP); A61P 5/50 (2018.01 - EP)

C-Set (source: EP)

  1. A61K 38/28 + A61K 31/44
  2. A61K 38/28 + A61K 31/425
  3. A61K 38/28 + A61K 31/41
  4. A61K 38/28 + A61K 2300/00

Citation (third parties)

Third party :

  • EP 0749751 A2 19961227 - TAKEDA CHEMICAL INDUSTRIES LTD [JP]
  • TANAKA ET AL: "Usefulness of CS-045 in NIDDM Patients under Treatment with Insulin", TONYOBYOU (DIABETES), vol. 37, no. 2, 1994, pages 139 (6), XP000667295
  • DATABASE DIALOG F-D-C REPORTS 1 January 1900 (1900-01-01), "WARNER-LAMBERT'S ATORVASTATIN COMPARISON TO OTHER STATINS SHOWS HIGHER EFFICACY COMPANY SAYS: ANTI-DIABETIC***TROGLITAZONE*** NDA FILING BY DECEMBER 1996", XP000667296
  • H.TAKINO ET AL: "Increased Insulin Responsiveness after CS-045 Treatment in Diabetes Associated with Werner's Syndrome", DIABETES RESEARCH AND CLINICAL PRACTICE, vol. 24, no. 3, July 1994 (1994-07-01), pages 162 - 172, XP000667297

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9705875 A2 19970220; WO 9705875 A3 19970327; AU 6641196 A 19970305; AU 724989 B2 20001005; BG 102235 A 19980930; CA 2221241 A1 19970220; CN 1192683 A 19980909; CZ 32998 A3 19981014; EA 199800177 A1 19981029; EP 0851757 A2 19980708; HU P9802543 A2 19990728; IL 122191 A0 19980405; JP H11510508 A 19990914; KR 19990036290 A 19990525; NO 980556 D0 19980209; NO 980556 L 19980209; NZ 313874 A 20000929; SK 16498 A3 19990312

DOCDB simple family (application)

US 9612430 W 19960729; AU 6641196 A 19960729; BG 10223598 A 19980205; CA 2221241 A 19960729; CN 96196191 A 19960729; CZ 32998 A 19960729; EA 199800177 A 19960729; EP 96926171 A 19960729; HU P9802543 A 19960729; IL 12219196 A 19960729; JP 50847997 A 19960729; KR 19980700958 A 19980209; NO 980556 A 19980209; NZ 31387496 A 19960729; SK 16498 A 19960729